Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rachel Brucas

Physician Assistant Evergreen Park, IL Physician Assistant

NPI 1457894768 CMS profile 10498088

9760 S Kedzie Ave, Evergreen Park, IL 60805

Open in the dashboard

General payments

$14,406

698 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachel Brucas of Evergreen Park, IL is reported in the CMS Open Payments database as having received $14,406 across 698 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,489 167
2024 General $2,700 144
2023 General $2,438 118
2022 General $3,116 156
2021 General $2,663 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachel Brucas
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Rachel Brucas were reported at $3,489. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Rachel Brucas Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,663 $132 $37–$438 $132
2022 $3,116 $155 $48–$522 $149
2023 $2,438 $167 $52–$557 $160
2024 $2,700 $178 $55–$600 $164
2025 $3,489 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $5,413 294 payments
  2. Lilly USA, LLC $1,193 62 payments
  3. Amgen Inc. $1,031 43 payments
  4. AstraZeneca Pharmaceuticals LP $924 50 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $602 21 payments
  6. Pfizer Inc. $581 29 payments
  7. Novo Nordisk Inc $559 31 payments
  8. GlaxoSmithKline, LLC. $487 23 payments
  9. Organon LLC $331 11 payments
  10. Allergan Inc. $266 9 payments
  11. Other $3,021 125 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,372 695 payments
  2. Education $35 3 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $2,410 154 payments
  2. QULIPTA $1,051 69 payments
  3. MOUNJARO $837 42 payments
  4. BOTOX $777 39 payments
  5. VRAYLAR $692 31 payments
  6. Otezla $595 25 payments
  7. Repatha $451 22 payments
  8. TRELEGY ELLIPTA $448 21 payments
  9. NURTEC ODT $434 21 payments
  10. FARXIGA $417 17 payments
  11. Other $8,081 393 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

996

Median for Physician Assistant: 241

Drug cost

$101,391

Median for Physician Assistant: $4,110

Branded share of claims

19.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 22 $33,229
Ozempic Semaglutide Brand 16 $24,659
Eliquis Apixaban Brand 17 $20,818
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $12,451
Atorvastatin Calcium Generic 109 $1,237
Adacel Tdap Diph,pertuss(Acell),tet Vac/Pf Brand 15 $1,033
Synthroid Levothyroxine Sodium Brand 17 $909
Rosuvastatin Calcium Generic 46 $645
Losartan Potassium Generic 48 $618
Omeprazole Generic 27 $471

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $308
$308 — —
QULIPTA
  • AbbVie, Inc. $202
$202 — —
MOUNJARO
  • Lilly USA, LLC $196
$196 22 —
UBRELVY
  • AbbVie, Inc. $187
$187 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $155
  • Lilly USA, LLC $3
$159 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

698 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record